Last updated 16 days ago
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
144 patients around the world
Available in Chile, Argentina, United States
Merck Sharp & Dohme LLC
10Research sites
144Patients around the world
This study is for people with
Skin cancer
Melanoma
Lung cancer
Non-small cell lung carcinoma
Kidney cancer
Renal cell carcinoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Instituto San Marcos Investigación - San Juan
Recruiting
Instituto de Investigaciones Clínicas Mar del Plata
Recruiting
Fundación Respirar
Recruiting
Centro de Investigación Clínica Bradford Hill - Santiago, Región Metropolitana
Recruiting
Oncocentro APYS - Valparaíso
Recruiting
Instituto Oncológico FALP - UIDO
Recruiting
James Lind Centro de Investigación del Cáncer - Temuco
Recruiting
Clínica Puerto Montt
Recruiting
Oncovida - Santiago
Recruiting
Hospital Clínico Pontificia Universidad Católica de Chile - Santiago, Región Metropolitana
Recruiting
StudyMK-3475A-F11
SponsorMerck Sharp & Dohme LLC
Conditions
MelanomaLung cancerNon-small cell lung carcinomaRenal cell carcinomaKidney cancer
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06099782
